• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

The KATHERINE trial: trastuzumab emtansine more effective than trastuzumab alone for treating residual HER2-positive breast cancer

byDayton McMillan
February 21, 2019
in Obstetrics, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Patients with residual human epidermal growth factor receptor 2 (HER2)-positive breast cancer after chemotherapy and HER2 targeted therapy had higher disease-free survival if treated with trastuzumab emtansine as opposed to trastuzumab alone.

2. More adverse events and serious adverse events occurred in patients treated with trastuzumab emtansine.

Evidence Rating Level: 1 (Excellent)      

Study Rundown: Among patients with HER2-positive breast cancer, patients with residual invasive disease at surgery after chemotherapy and HER2-targeted treatment often have poor clinical outcomes. Currently, patients with residual disease often undergo HER2-target therapy, though combination of HER2-target therapy plus another agent may provide superior clinical outcomes. The KATHERAINE trial sought to evaluate invasive disease-free survival of patients with residual HER2-positive breast cancer when treated with combination trastuzumab emtansine versus trastuzumab alone. Results indicated significantly improved survival in the combination therapy group. Distant recurrence rates were also significantly lower in the combination therapy group.

This study suggests greater survival outcomes are possible even after patients with residual disease have received HER2-targeted therapy, though its limitation in patients with residual disease were not tested to confirm persistent HER2-positive status.

Click to read the study in NEJM

Relevant Reading: Trastuzumab emtansine for HER2-positive advanced breast cancer

RELATED REPORTS

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

Religious-based interventions improve illness perception in breast cancer patients

Wellness Check: Spirituality

In-Depth [randomized controlled trial]: This multicenter, phase 3, randomized controlled trial enrolled patients between 2013 and 2015. Eligible patients had histologically confirmed HER2-positive invasive breast cancer and residual disease after treatment with chemotherapy and trastuzumab for a prespecified period of time. Patients were randomized in a 1:1 fashion to trastuzumab (n=743) of trastuzumab emtansine (n=743) groups after surgery with stratification for clinical stage and hormone receptor status at presentation. Treatment out to 14 cycles with combination or trastuzumab therapy was performed. The primary outcome was invasive disease-free survival, which includes freedom from death, distant recurrence, or various local sites of breast cancer recurrence. Clinical assessment of disease recurrence occurred every 3 months until year 2, then every 6 months until year 5, then every year until year 10. Invasive disease-free survival was greater in the combination therapy group compared to those treated with trastuzumab (hazard ratio [HR], 0.50; 95%CI, 0.39 to 0.64; P<0.001). Patients estimated to be disease-free at 3 years post-randomization was 88.3% in the combination group and 77.0% in the trastuzumab group. Risk of distant metastasis was lower in the combination therapy group (HR, 0.60; 95% CI, 0.45 to 0.79). With subgroup analysis, all subgroups were shown to have superior or indeterminant invasive disease-free survival outcomes when treated with trastuzumab emtansine. There was no significant difference observed in overall survival outcomes between groups. Patients completed all 14 cycles of therapy in 71.4% and 81.0% of combination and trastuzumab therapy, respectively. Serious adverse events (grade 3 or higher) occurred in 25.7% and 15.4% of combination and trastuzumab therapy patients, respectively.

Image: PD

©2019 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc

Tags: Breast Canceremtansinetrastuzumab
Previous Post

#VisualAbstract: Intravenous Iron in Patients Undergoing Maintenance Hemodialysis

Next Post

Chinese population study shows high prevalence of elevated cardiovascular disease risk and low utilization of pharmacotherapy

RelatedReports

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer
StudyGraphics

#VisualAbstract: Tamoxifen increases the risk of endometrial cancer in premenopausal women with breast cancer

January 24, 2023
Palliative care consultation linked to lower deaths by failed code resuscitation
Oncology

Religious-based interventions improve illness perception in breast cancer patients

January 9, 2023
Early palliative care may improve survival in advanced cancer
Wellness

Wellness Check: Spirituality

January 5, 2023
Oncology

Patients with HER2-positive advanced breast cancer and pathological complete response to neoadjuvant systemic therapy may not require surgical intervention

October 31, 2022
Next Post
Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors

Chinese population study shows high prevalence of elevated cardiovascular disease risk and low utilization of pharmacotherapy

Quick Take: Association of Systemic Antibiotic Treatment of Acne With Skin Microbiota Characteristics

Quick Take: Association of Systemic Antibiotic Treatment of Acne With Skin Microbiota Characteristics

Herpes zoster vaccine not cost-effective for 50 year-old adults

New herpes zoster vaccine predicted to be more cost effective than predecessor  

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options